EQS-News: Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes
Formycon reports nine-month results for 2024 and continues growth trajectory with further operational success Excellent third quarter with product approvals for FYB202 in the key markets USA and ...
Optimistic Outlook on Doximity: Benefiting from Shifts in Pharmaceutical Advertising and Strong Growth Potential
In a report released today, Glen Santangelo from Jefferies maintained a Buy rating on Doximity (DOCS – Research Report), with a price target of ...
Skeletal Dysplasia Treatment Market Analysis by Type, End User, Region and Company - Forecast to 2030
BioMarin Pharmaceutical, Alexion Pharmaceuticals, Amgen, Eli Lilly & Company, and Novartis Dominate the Competitive Landscape ...